Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGonzález Astorga, B.
dc.contributor.authorSalva Ballabrera, Francesc
dc.contributor.authorAranda Aguilar, Enrique
dc.contributor.authorElez Fernandez, Mª Elena
dc.contributor.authorGarcía‑Alfonso, P.
dc.contributor.authorGonzález Flores, E.
dc.date.accessioned2022-01-24T14:29:20Z
dc.date.available2022-01-24T14:29:20Z
dc.date.issued2021-08
dc.identifier.citationGonzález Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, et al. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol. 2021 Aug;23:1520–1528.
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/11351/6884
dc.descriptionAflibercept; Colorectal cancer; Patient profile
dc.description.abstractColorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient’s profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesClinical and Translational Oncology;23
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCòlon - Càncer - Quimioteràpia
dc.subjectRecte - Càncer - Quimioteràpia
dc.subjectQuimioteràpia combinada
dc.subject.meshColorectal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.mesh/therapeutic use
dc.titlePatient profiles as an aim to optimize selection in the second line setting: the role of aflibercept
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s12094-021-02568-y
dc.subject.decsneoplasias colorrectales
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.subject.decs/uso terapéutico
dc.relation.publishversionhttps://doi.org/10.1007/s12094-021-02568-y
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[González Astorga B] Hospital Universitario Clínico San Cecilio, Granada, Spain. [Salvà Ballabrera F, Élez Fernández E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aranda Aguilar E] Hospital Universitario Reina Sofía, Córdoba, Spain. [García-Alfonso P] Hospital General Universitario Gregorio Marañón, Madrid, Spain. [González Flores E] Hospital Universitario Virgen de Las Nieves, Granada, Spain
dc.identifier.pmid33630242
dc.identifier.wos000621755500002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record